Haleos Labs Limited Upgraded to Hold as Technicals Improve and Valuation Attracts

Technical Indicators Shift to Mildly Bullish

The primary catalyst for the upgrade lies in the technical trend, which has transitioned from mildly bearish to mildly bullish. On a daily basis, moving averages now indicate a mildly bullish stance, suggesting short-term momentum is gaining strength. However, weekly and monthly MACD readings remain mildly bearish, while the monthly RSI continues to show bearish tendencies. Bollinger Bands reveal a bearish trend on the weekly chart but sideways movement monthly, indicating consolidation rather than a clear directional bias.

Other technical tools such as the KST oscillator remain mildly bearish on both weekly and monthly timeframes, and Dow Theory along with On-Balance Volume (OBV) show no definitive trend. Despite these mixed signals, the daily moving averages’ mild bullishness has been sufficient to nudge the overall technical grade upward, reflecting a tentative shift in market sentiment.

Valuation Remains Attractive Amid Discount to Peers

From a valuation perspective, Haleos Labs Limited presents an attractive proposition. The company’s Return on Capital Employed (ROCE) stands at 11%, which is respectable within its sector. Its Enterprise Value to Capital Employed ratio is a modest 1.7, indicating the stock is trading at a discount relative to its peers’ historical valuations. This discount is particularly notable given the company’s micro-cap status, which often entails higher volatility but also potential for upside.

Despite a recent one-year profit decline of 13.9%, the stock has delivered a 13.94% return over the same period, outperforming the BSE500 benchmark. Over longer horizons, Haleos Labs has significantly outpaced the Sensex, generating returns of 130.03% over three years and 136.89% over five years, compared to Sensex returns of 33.74% and 64.38% respectively. This long-term outperformance underpins the valuation appeal despite short-term profit pressures.

Financial Trend Shows Mixed Signals but Positive Quarterly Performance

Financially, Haleos Labs has demonstrated encouraging signs in the recent quarter Q3 FY25-26. Net sales reached a quarterly high of ₹94.78 crores, while the operating profit to interest coverage ratio surged to 9.12 times, indicating robust operational efficiency and strong ability to service debt. The company’s debt-equity ratio remains low at 0.34 times, underscoring a conservative capital structure that mitigates financial risk.

However, the longer-term financial trend is less compelling. Over the past five years, net sales have grown at a modest annual rate of 8.71%, and operating profit has increased by 13.38% annually. The average ROCE over the long term is 9.15%, which is below the recent quarterly figure and suggests some inconsistency in capital utilisation efficiency. Additionally, profits have declined by 13.9% over the last year, tempering enthusiasm despite the positive quarterly results.

Quality Assessment and Market Position

Haleos Labs holds a Mojo Score of 50.0 and a Mojo Grade of Hold, upgraded from Sell. This reflects a balanced view of the company’s prospects, with neither strong buy nor sell signals dominating. The company remains a micro-cap within the Pharmaceuticals & Biotechnology sector, with promoters holding the majority stake, which often aligns management interests with shareholders.

The stock price currently stands at ₹1,278.40, slightly down from the previous close of ₹1,287.30. It trades well above its 52-week low of ₹989.05 but remains below the 52-week high of ₹1,680.00, indicating room for price appreciation if positive trends continue. The stock’s recent one-week return was -0.63%, underperforming the Sensex’s 3.81% gain, but it has outperformed over longer periods, including a 14.4% return in the last year versus Sensex’s 4.44%.

Balancing Strengths and Weaknesses for a Hold Recommendation

The upgrade to Hold reflects a balanced assessment of Haleos Labs Limited’s current standing. The improved technical indicators, particularly the shift to mildly bullish daily moving averages, provide a near-term positive signal. Valuation metrics suggest the stock is attractively priced relative to peers, supported by solid quarterly financial performance and a conservative debt profile.

Conversely, the company’s long-term growth rates and profitability trends remain subdued, with profit declines over the past year and modest sales growth over five years. The mixed technical signals on weekly and monthly charts, alongside a moderate Mojo Score, caution against a more aggressive Buy rating at this stage.

Investors should monitor upcoming quarterly results and technical developments closely, as sustained improvements in profitability and clearer bullish technical trends could warrant a further upgrade. For now, the Hold rating recognises Haleos Labs as a stable but cautious opportunity within the Pharmaceuticals & Biotechnology sector.

Summary of Key Metrics:

• Mojo Score: 50.0 (Hold, upgraded from Sell on 13 Apr 2026)
• Current Price: ₹1,278.40; 52-week range: ₹989.05 - ₹1,680.00
• ROCE: 11% (attractive valuation)
• Debt-Equity Ratio: 0.34 times (low leverage)
• Operating Profit to Interest Coverage: 9.12 times (strong)
• Net Sales (Q3 FY25-26): ₹94.78 crores (highest quarterly figure)
• 1-Year Return: 13.94% vs Sensex 4.44%
• 3-Year Return: 130.03% vs Sensex 33.74%
• 5-Year Return: 136.89% vs Sensex 64.38%

Overall, Haleos Labs Limited’s upgrade to Hold is a reflection of improved technical momentum and valuation appeal, tempered by mixed financial trends and moderate quality scores. This nuanced stance offers investors a reason to maintain exposure while awaiting clearer signals for a more decisive investment call.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today